Last updated: February 19, 2026
Mexico's patent framework for biopharmaceuticals presents specific considerations for patentability, enforceability, and claim scope. Understanding these nuances is critical for R&D and investment decisions.
What are the Key Patentability Requirements for Biopharmaceuticals in Mexico?
In Mexico, patentability for biopharmaceuticals is governed by the Industrial Property Law (IPL) and its regulations. To be patentable, an invention must meet three core criteria: novelty, inventive step (non-obviousness), and industrial applicability.
Novelty
An invention is considered new if it has not been disclosed to the public, anywhere in the world, prior to the filing date of the patent application. This includes publications, public use, sale, or any other means of disclosure. For biopharmaceuticals, this means prior art searches must be comprehensive, covering scientific literature, existing patents, and any public disclosures by the applicant.
Inventive Step (Non-obviousness)
An invention involves an inventive step if, for a person skilled in the art, it is not obvious from the prior art. This is a critical hurdle for biopharmaceutical inventions, which often build upon existing knowledge. Demonstrating that a biopharmaceutical offers unexpected results, superior efficacy, or a novel mechanism of action is crucial. For instance, a new formulation of an existing drug might be patentable if it provides a significant therapeutic advantage not predictable from the known properties of the active ingredient.
Industrial Applicability
The invention must be capable of being made or used in any kind of industry, including agriculture. For biopharmaceuticals, this generally translates to the ability to be manufactured and have a practical therapeutic or diagnostic use.
Specific Considerations for Biopharmaceuticals
Mexican patent law, similar to international standards, does not explicitly exclude methods of treatment of the human or animal body from patentability. However, claims directed to these methods are generally not granted. Instead, patents are typically sought for:
- Substances or compositions: This includes active pharmaceutical ingredients (APIs), formulations, and combinations.
- Processes for manufacturing: Methods to produce the API or the final drug product.
- Use claims: First or second medical use claims can be patentable if the use is new and inventive. For example, a new therapeutic use for a known compound could be protected.
Table 1: Key Patentability Criteria in Mexico
| Criterion |
Description |
Biopharmaceutical Relevance |
| Novelty |
The invention has not been publicly disclosed prior to the filing date. |
Requires thorough prior art searches of scientific literature, databases, and existing patents. Disclosure of research findings or early-stage clinical data can anticipate a later patent application. |
| Inventive Step |
The invention is not obvious to a person skilled in the art, considering the prior art. |
Crucial for demonstrating improvements in efficacy, safety, pharmacokinetics, or novel mechanisms of action. Unexpected synergistic effects in drug combinations are a common basis for demonstrating inventiveness. |
| Industrial Applicability |
The invention can be made or used in any kind of industry. |
Relates to the ability to manufacture the API, formulate the drug, and demonstrate a practical therapeutic or diagnostic application. |
| Sufficiency of Disclosure |
The patent application must describe the invention in a manner sufficiently clear and complete for a person skilled in the art to carry it out. |
Requires detailed description of the biological material, its source, characterization, methods of production, and intended use. Deposit of biological material may be required in certain cases. |
| Unity of Invention |
The application must relate to a single invention or a group of inventions so linked as to form a single general inventive concept. |
May be an issue for applications claiming multiple compounds, formulations, or uses without a clear unifying inventive concept. |
Exclusions from Patentability: Mexico, like many jurisdictions, excludes certain subject matter from patentability. These exclusions include scientific theories, mathematical methods, abstract ideas, and diagnostic, therapeutic, and surgical methods for the treatment of the human or animal body. However, products used in these methods (e.g., drugs, instruments) are patentable. [1]
Support for Biologics: While the IPL doesn't specifically define "biologic," patent protection extends to biological materials and processes. This includes genes, proteins, antibodies, and microorganisms, provided they meet the general patentability requirements. The novelty and inventive step for biologics often lie in their unique sequence, structure, function, or therapeutic effect. [2]
How is Patent Enforceability Addressed for Biopharmaceuticals in Mexico?
Enforcing biopharmaceutical patents in Mexico involves navigating the legal system and understanding the specific remedies available.
Infringement Determination
Patent infringement occurs when a third party makes, uses, sells, offers for sale, or imports a patented invention without the patent holder's authorization. For biopharmaceuticals, infringement can relate to:
- Unauthorized manufacturing or sale of the patented drug: This is the most direct form of infringement.
- Use of a patented process: If a company uses a patented method to produce a drug, it can be liable for infringement.
- Importation of infringing products: Bringing a drug into Mexico that infringes a valid Mexican patent is also an infringement.
The scope of the patent claims dictates what constitutes infringement. A detailed claim analysis is essential to determine if a competitor's product or process falls within the protected scope.
Legal Proceedings
Patent disputes in Mexico are typically handled by the Mexican Institute of Industrial Property (IMPI) for administrative proceedings and by federal courts for civil litigation.
Administrative Proceedings at IMPI
IMPI handles opposition proceedings, nullity actions, and patent infringement inquiries. For infringement, IMPI can issue cease and desist orders and impose fines.
Civil Litigation
Civil lawsuits are filed in federal courts. Remedies available include:
- Injunctions: A court order to stop the infringing activity.
- Damages: Compensation for financial losses incurred due to the infringement. This can include lost profits or reasonable royalties.
- Seizure and destruction of infringing goods: The court can order the confiscation and destruction of counterfeit or infringing products.
Data Exclusivity and Market Protection
While not a patent right, data exclusivity is a crucial aspect of market protection for biopharmaceuticals in Mexico. Under Mexican law, regulatory authorities grant a period of data exclusivity to originators of innovative drugs. This period prevents generic manufacturers from relying on the originator's clinical trial data to obtain marketing approval.
- Data Exclusivity Period: Typically, this period is for eight years from the date of marketing authorization for patented new drugs. For follow-on biologics, it is six years. [3]
This mechanism provides a supplementary layer of market protection, extending beyond the patent term and acting as a deterrent against rapid generic entry.
Challenges in Enforcement
- Burden of Proof: The patent holder generally bears the burden of proving infringement. This can be challenging, especially when the infringing activity occurs behind closed doors (e.g., manufacturing processes).
- Timeliness of Proceedings: Legal and administrative proceedings can be lengthy, potentially allowing infringing activities to continue for a considerable period.
- Counterfeiting: The prevalence of counterfeit drugs can complicate enforcement efforts, requiring a multi-pronged strategy involving IMPI, customs authorities, and internal surveillance.
Table 2: Enforcement Mechanisms for Biopharmaceutical Patents in Mexico
| Mechanism |
Description |
Relevance for Biopharmaceuticals |
| Patent Infringement Action (Civil) |
A lawsuit filed in federal court seeking remedies for unauthorized use of a patented invention. |
Crucial for stopping direct copying of patented drugs, formulations, or manufacturing processes. Allows for seeking injunctions, damages, and seizure of infringing goods. |
| Administrative Infringement Inquiry |
An investigation initiated at IMPI, which can lead to cease and desist orders and fines. |
A faster, though often less comprehensive, route to halt infringing activities. Useful for addressing clear-cut cases of market sales of infringing products. |
| Data Exclusivity |
Regulatory protection preventing generic manufacturers from relying on originator's clinical trial data for a specified period. |
Extends market exclusivity beyond patent life. Protects the investment in R&D and clinical trials by preventing immediate generic competition based on regulatory data, even if the patent has expired or is challenged. |
| Customs Enforcement |
Detention of infringing goods at the border by customs authorities based on a patent holder's request. |
An important tool for preventing the importation of counterfeit or infringing biopharmaceutical products into Mexico. Requires proactive engagement with customs officials. |
| Discovery Process |
The pre-trial exchange of information between parties, including documents and witness testimony. |
Can be challenging in Mexico compared to common law jurisdictions. Access to competitor's internal manufacturing or research data may be limited. |
| Opposition Proceedings |
Third parties can challenge the validity of a granted patent at IMPI. |
Competitors may initiate these proceedings to invalidate a patent. Patent holders must be prepared to defend their patents and demonstrate their validity. |
| Nullity Actions |
A legal action in federal court to declare a patent invalid. |
Similar to opposition proceedings but pursued through the judicial system. |
What is the Scope of Claims for Biopharmaceutical Patents in Mexico?
The scope of claims in a biopharmaceutical patent in Mexico defines the extent of protection granted. This is determined by the language of the claims themselves and how they are interpreted by IMPI and the courts.
Types of Claims and Their Scope
- Composition of Matter Claims: These are generally considered the strongest and broadest claims. They cover the physical substance of a compound, formulation, or biological entity. For biopharmaceuticals, this would include claims to a specific antibody, protein, DNA sequence, or a pharmaceutical composition containing them.
- Example: A claim to "A humanized monoclonal antibody that binds to PD-1 with an affinity of X nM and blocks the interaction between PD-1 and PD-L1."
- Process Claims: These claims cover methods of making or using an invention. For biopharmaceuticals, this could include claims to a novel method of manufacturing a protein, a gene therapy delivery method, or a method of cell culture.
- Example: A claim to "A method of producing recombinant human growth hormone comprising culturing E. coli in a fermentation medium containing Y nutrient."
- Use Claims (First and Second Medical Use): While methods of treatment are not directly patentable, new uses for known compounds can be patented.
- First Medical Use: This covers the initial therapeutic indication for a known compound. If a compound is known, but its therapeutic use is new, it can be patented.
- Second Medical Use: This covers a new therapeutic use for a compound that is already known and used for a different indication. These claims are often drafted as "substance X for use in treating disease Y" or "a method of treating disease Y comprising administering substance X." The latter form, when allowed, is essentially a claim to a method of treatment limited to a specific disease.
- Example (Second Medical Use): A claim to "Antibody A for use in treating autoimmune disease B."
Claim Interpretation
Mexican patent law and jurisprudence follow principles of claim interpretation that are largely consistent with international standards. The interpretation considers:
- The literal meaning of the claim language: The plain meaning of the words used in the claim.
- The patent specification and drawings: These documents provide context and help define the scope of the claims.
- The prosecution history: Amendments made to the claims during examination can limit their scope.
- The doctrine of equivalents: This doctrine may allow for protection against equivalents of the claimed invention, even if not literally falling within the claim language, provided they perform substantially the same function in substantially the same way to achieve substantially the same result. However, the application of this doctrine can vary and requires careful legal analysis. [4]
Specific Considerations for Biologics
- Product-by-Process Claims: These claims define a product by the process used to make it. They are sometimes used for biologics when defining the product itself is difficult. However, these claims are generally disfavored and may be held invalid if the product itself can be adequately defined and is novel and inventive.
- Markush Claims: These are used to claim a group of related chemical compounds or structures. In biopharmaceuticals, they can be used to claim a class of antibodies with specific binding characteristics or a class of related therapeutic proteins.
- Example: A Markush claim might describe a generic structure for a protein binding domain where variations are indicated by variable substituents.
- Gene Sequence and Protein Claims: Claims can be directed to isolated DNA sequences (genes), RNA sequences, or protein sequences. The patentability hinges on demonstrating that these are novel, not naturally occurring in their isolated form, and have industrial applicability. [2]
Impact of Patent Term Extensions
The patent term for pharmaceuticals can be extended in Mexico to compensate for regulatory delays. The maximum extension is generally five years, applied to the patent term that has not yet expired. This extension can significantly enhance the market protection period for biopharmaceutical products. [5]
Table 3: Scope of Claims for Biopharmaceutical Patents
| Claim Type |
Description |
Breadth & Strength for Biopharmaceuticals |
| Composition of Matter |
Claims directed to the physical substance of an active ingredient, formulation, or biological entity. |
Generally the broadest and strongest protection. Covers the substance itself, irrespective of how it is made or used. Essential for protecting novel antibodies, proteins, small molecules, and their formulated versions. |
| Process Claims |
Claims directed to methods of manufacturing or producing a biopharmaceutical. |
Crucial for protecting proprietary manufacturing technologies, especially for complex biologics where the production process is critical. Offers protection against competitors using the same efficient or unique manufacturing pathway, even if they develop a slightly different final product. |
| First Medical Use |
Claims for a new therapeutic use of a known compound or substance. |
Protects the initial discovery of a therapeutic benefit for a substance. Useful when a compound's therapeutic potential is elucidated after its initial development or when repurposing existing drugs. |
| Second Medical Use |
Claims for a new therapeutic use of a compound or substance that is already known and has at least one approved medical use. |
Offers protection for novel applications of existing drugs or biologics. Often drafted as "substance for use in treating disease X" or "method of treating disease X comprising administering substance Y." While methods of treatment are excluded, specific use claims are patentable. |
| Product-by-Process |
Claims defining a product by the method of its manufacture. |
Can be a fallback position for defining novel biologics where the precise characterization of the product is challenging. However, generally weaker than direct product claims and may be challenged if the product itself can be sufficiently defined. |
| Gene/Protein Sequence |
Claims directed to isolated DNA, RNA, or protein sequences. |
Protects the genetic material or protein structure itself. Patentability requires demonstrating that the isolated sequence is novel and has industrial applicability, often relating to its therapeutic or diagnostic function. The "naturally occurring" exclusion is a key consideration. |
| Markush Claims |
Claims covering a generic structure with variable substituents, defining a class of related compounds or molecules. |
Provides broader protection for a family of related biopharmaceutical entities, such as variations in antibody CDR regions or amino acid substitutions in a therapeutic protein, that share a common inventive concept and likely therapeutic profile. |
| Polymorphs/Formulations |
Claims directed to specific crystalline forms of an active ingredient or novel pharmaceutical compositions. |
Can provide secondary protection by covering new physical forms of a drug or improved delivery systems. Demonstrating improved properties (e.g., bioavailability, stability, solubility) is key to patentability and enforceability. |
Key Takeaways
- Biopharmaceutical patentability in Mexico requires strict adherence to novelty, inventive step, and industrial applicability criteria, with specific nuances for biological materials and medical uses.
- Enforcement relies on civil litigation and administrative actions through IMPI, complemented by data exclusivity and customs measures.
- Claim scope is determined by careful drafting, encompassing composition of matter, process, and medical use claims, with interpretation guided by established legal principles.
FAQs
-
Can a patent be obtained in Mexico for a new therapeutic use of a drug already approved for a different condition?
Yes, a patent can be obtained for a new therapeutic use of a known compound or substance, often termed a "second medical use" claim, provided the new use is novel and involves an inventive step.
-
What is the typical duration of patent protection for a biopharmaceutical in Mexico?
The standard patent term in Mexico is 20 years from the filing date. However, for pharmaceuticals and medical devices, a patent term extension of up to five years can be granted to compensate for regulatory approval delays, provided the patent has not yet expired.
-
Are methods of treatment of the human body patentable in Mexico?
Direct methods of treatment of the human or animal body are excluded from patentability. However, products used in such treatments, like drugs, and specific use claims for treating a particular disease are patentable.
-
Does Mexico have provisions for patent linkage (e.g., "Orange Book" system) to prevent generic drug approval during patent pendency or term?
Mexico does not have a direct "Orange Book" equivalent that automatically stays generic approval based on pending patents. However, data exclusivity provisions and the ability to seek injunctions in patent infringement cases provide indirect market protection.
-
What is the role of IMPI in biopharmaceutical patent disputes?
IMPI (Instituto Mexicano de la Propiedad Industrial) is the primary government agency responsible for industrial property rights in Mexico. It handles patent examinations, grants patents, and manages administrative proceedings related to patent infringement inquiries, oppositions, and revocations.
Citations
[1] Ley de la Propiedad Industrial [LPI] (Mexico).
[2] World Intellectual Property Organization. (n.d.). Patentability of Biogenetic Resources and Products. Retrieved from WIPO resources on national patent laws.
[3] Ley General de Salud [LGS] (Mexico). Article 167.
[4] Mexican Jurisprudence and administrative decisions on patent interpretation. (Accessed via legal databases and IMPI publications).
[5] Ley de la Propiedad Industrial [LPI] (Mexico), Article 23 bis.
